[1. Jandrichova S, Vcelak J, Vlcek P, Neradilova M, Nemec J, Bendlova B. Screening of six risk exons of the ret proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic. Journal of Endocrinology. 2004; 183: 257-265.10.1677/joe.1.05838]Search in Google Scholar
[2. National Cancer Institute. MedullaryThyroid Cancer. available at: http://www.cancer.gov/cancertopics/pdq/genetics/medullarythyroid/HealthProfessional/page2/print]Search in Google Scholar
[3. Eng Charis. Ret proto-oncogene in the development of human cancer. J Clin Oncol. 1999; 17(1): 380-393.10.1200/JCO.1999.17.1.380]Search in Google Scholar
[4. Maitra A, Abbas A. K. The endocrine system. In: Robbins and Cotran Pathologic basis of Disease. 7th edition, Philadelphia (Pennsylvania): Elsevier Saunders; 2005. 1155-1226.]Search in Google Scholar
[5. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gangel R. F, et al. The relationship between specific ret proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996; 276: 1575-1579.10.1001/jama.1996.03540190047028]Search in Google Scholar
[6. Matias-Guiu X, DeLellis R, Moley J. F, Gagel R. F, Slbores-Saavedra J, Bussolati G. et al. Medullary thyroid carcinoma. In: Pathology and genetics of tumors of endocrine system. World Health Organization Classification of Tumors, IARC, Lyon: IARC Press. 2001; 86-91.]Search in Google Scholar
[7. Cobanoglu B, Ozercan M.R. Staining characteristics of BCL-2, BAX, p53, p21, Ki-67 andC-erbB2 in thyroid carcinomas. Erciyes Medical Journal 2007; 29 (3): 201-209.]Search in Google Scholar
[8. Viale G, Roncalli M, Grimelius L, Graziani D, Wilander E, Johansson H, et al.: Prognostic value of bcl-2 immunoreactivity in medullary thyroid carcinoma. Hum Pathol. 1995; 26(9): 945-50.10.1016/0046-8177(95)90082-9]Search in Google Scholar
[9. Gerasimovski D. Census of population, households and dwellings in the Republic of Macedonia, 2002 Final data. Republic of Macedonia State Statistical Office. Book X. 2002; 10: 18-197.]Search in Google Scholar
[10. Mograbi B, Bocciardi R, Bourget I, Juhel T, Farahi- Far D, Romeo G, et al. The sensitivity of activated Cys Ret mutants to glial cell line-derived neuritrophic factor is mandatory to rescue neuroectodermal cells from apoptosis. Mol Cell Biol. 2001; 21(20): 6719-6730.10.1128/MCB.21.20.6719-6730.20019985011564857]Search in Google Scholar
[11. Komminoth P. The role of ret proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN2) gene carriers and the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas. Verh Dtsch Ges Pathol. 1995; 79: 50-55.]Search in Google Scholar
[12. Quayle F. J, Fialkowski E. A, Benveniste R, Moley J. F. Pheochromocytoma penetrance varies by Ret mutation in MEN2A. Surgery. 2007; 142(6): 800-805.10.1016/j.surg.2007.09.01318063059]Search in Google Scholar
[13. Shirahama S, Ogura K, Takami H, Ito K, Tohsen T, Myiauchi A, et al. Mutational analysis of the ret proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma. J Hum Genet.1998; 43(2): 101-106.10.1007/s1003800500489621513]Search in Google Scholar
[14. Linwah Y, Cote G.. J, Shapiro S. E, Ayers G. D, Herzog C. E, Sellin R. V, et al. Multiple endocrine neoplasia type 2. Evaluation of genotype-phenotype relationship. Arch Surg. 2003; 138: 409-416.10.1001/archsurg.138.4.40912686527]Search in Google Scholar
[15. Arighi E, Popsueva A, Degl’Innocenti D, Borrello M. G, Carniti C, Perala N. M, et al. Biological effects of dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschprung’s disease. Mol Endocrinol. 2004; 18(4): 1004-1017.10.1210/me.2003-017314715928]Search in Google Scholar
[16. Skinner M. A, Safford S. D, Reeves J. G, Jackson M. E, Freemerman A. J. Renal aplasia in humans is associated with Ret mutations. Am J Hum Genet. 2008; 82(2): 344-51.10.1016/j.ajhg.2007.10.008242729318252215]Search in Google Scholar
[17. Sanjay J, Encinas M, Johnson E. M Jr, Milbrandt J. Critical and distinct roles for key Ret tyrosine docking sites in renal development. Genes & Development. 2006; 20: 321-333.10.1101/gad.1387206136170316452504]Search in Google Scholar
[18. Yu O. H, Murawski I. J, Myburgh D. B, Gupta I. R. Overexpression of Ret leads to vesicoureteric reflux in mice. Am J Physiol Renal Physiol. 2004; 287: 1123-1130.10.1152/ajprenal.00444.200315328070]Search in Google Scholar
[19. Yang Y, Houle A-M, Letendre J, Richter A. Ret Gly691Ser mutation is associated with primary vesicoureteral reflux in the French-Canadian population from Quebec. Human Mutation. 2008; 29(5): 695-702.10.1002/humu.2070518273880]Search in Google Scholar
[20. Ensembl. Human gene view. available at: http://www.ensembl.org/Homo_sapiens/geneview?gene=OTTHUMG00000018024;db=vega]Search in Google Scholar
[21. Gene Cards. RET gene card. available at: http://www.genecards.org/cgi-bin/carddisp.pl?gene=RET]Search in Google Scholar
[22. Berndt I, Reuter M, Saller B, Frank-Raue K, Groth P, Grusendorf M, et al. A new hot spot for mutations in the ret proto-oncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab. 1998; 83(3): 770-774.]Search in Google Scholar
[23. Bolino A, Schuffenecker I, Luo Y, Seri M, Silengo M, Tocco T, et al. Ret mutations in exons 13 and 14 of FMTC patients. Oncogene. 1995; 10: 2415-2419.]Search in Google Scholar
[24. Eng C, Mulligan L. M, Smith D. P, Healey C. S, Frilling A, Raue F, et al. Mutation of the ret protooncogene in sporadic medullary thyroid carcinoma. Genes, Chromosomes and Cancer. 1995; 12: 209-212.10.1002/gcc.28701203087536460]Search in Google Scholar
[25. Fattoruso O, Quadro L, Libroia A, Verga U, Lupoli G, Cascone E, et al. A GTG to ATG novel point mutation at codon 804 in exon 14 of the ret protooncogene in two families affected by familial medullary thyroid carcinoma. Human Mutation. 1998; 1: 167-171.10.1002/humu.13801101569452077]Search in Google Scholar
[26. Da Silva A. M, Maciel R. M, Da Silva M. R, Toledo S. R, De Carvalho M. B, Cerutti J. M. A novel germline point mutation in ret exon 8 (Gly533Cys) in large kindred with familial medullary thyroid carcinoma. J Clin Endocrinol Metab. 2003; 88: 5438-5443.10.1210/jc.2003-03099714602786]Search in Google Scholar
[27. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab. 2008; 93(3): 682-687.10.1210/jc.2007-171418073307]Search in Google Scholar
[28. Eng C, Smith D. P, Mulligan L. M, Nagai M. A, Healey C. S, Ponder M. A et al. Point mutation within the thyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumors. Hum Mol Genet. 2003; 3(2): 237-241.10.1093/hmg/3.2.2377911697]Search in Google Scholar
[29. Hofstra R. M, Landsvater R. M, Ceccherini I, Stulp R. P, Stelwagen T, Luo Y, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 1994; 367(6461): 375-376.10.1038/367375a07906866]Search in Google Scholar
[30. Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin endocrinol Metab. 2007; 92(12): 4725-9.10.1210/jc.2007-100517895320]Search in Google Scholar
[31. Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F et al. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab. 1996; 81(4): 1619-22.]Search in Google Scholar
[32. Zedenius J, Wallin G, Hamberger B, Nordenskjold M, Weber G, Larsson C. Hum mol Genet. 1994; 3(8): 1259-62.]Search in Google Scholar
[33. Eng C, Mulligan L. M, Smith D. P, Healey C. S, Frilling A, Raue F, et al. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.Clin Endocrinol (Oxf). 1995; 43(1): 123-7.10.1111/j.1365-2265.1995.tb01903.x]Search in Google Scholar
[34. Blaugrund J. E, Johns M. M Jr, Eby Y. J, Ball D. W, Baylin S. B, Hruban R. H, Sidransky D. Hum Mol Genet. 1994; 3(10): 1895-7.]Search in Google Scholar
[35. Machens A, Dralle H. Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg. 2007; 31(5): 957-68.10.1007/s00268-006-0769-y]Search in Google Scholar
[36. Frank-Raue K, Machens A, Scheuba C, Niederle B, Dralle H, Raue F, the German MEN2 Study Group. Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791. Clin endocrinol (Oxf). 2008; Epub ahead of print. PMID 18248648.10.1111/j.1365-2265.2008.03215.x]Search in Google Scholar
[37. Elisei R, Cosici B, Romei C, Agate L, Piampiani P, Miccoli P, et al. Identification of novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition. J Clin Endocrinol Metab. 2004; 89(11): 5823-7.10.1210/jc.2004-0312]Search in Google Scholar
[38. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphism of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc. Natl. Acad. Sci. USA. 1989; 86: 2766-2770.10.1073/pnas.86.8.2766]Search in Google Scholar
[39. Glavac D, Dean M. Optimization of the singlestrand conformation polymorphism (SSCP) technique for detection of point mutations. Hum Mutat. 1993; 2(5): 404-414.10.1002/humu.1380020513]Search in Google Scholar
[40. Kumar P, Henikoff S, Ng P. C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009; 4(7): 1073-1081.10.1038/nprot.2009.86]Search in Google Scholar
[41. Choi Y, Sims G. E, Murphy S, Miller J. R, Chan A. P (2012) Predicting the Functional Effect of Amino Acid Substitutions and Indels. PLoS ONE 7(10): e46688. Available at: http://provean.jcvi.org/index.php10.1371/journal.pone.0046688]Search in Google Scholar
[42. StatSoft, Inc. (2001). STATISTICA (data analysis software system), version 6. www.statsoft.com.]Search in Google Scholar
[43. Desmet F. O, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acid Research, 2009. available at: http://www.umd.be/HSF/10.1093/nar/gkp215]Search in Google Scholar
[44. Schilling T, Burck J, Sinn H. P, Clemens A, Otto H. F, Hoppner W, et al. Prognostic value of codon 918(ATG>ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer. 2001; 95(1): 62-6.10.1002/1097-0215(20010120)95:1<62::AID-IJC1011>3.0.CO;2-1]Search in Google Scholar
[45. Leboulleux S, Baudin E, Travagli J. P, Schlumberger M. Medullary thyroid carcinoma. Clinical Endocrinology. 2004; 61: 299-310. doi: 10.1111/j.1365-2265.2004.02037.x 10.1111/j.1365-2265.2004.02037.x15355445]Search in Google Scholar